CLINICAL SURVEY OF PROSTATE CANCER
-
- Takada Tsuyoshi
- Department of Urology, Osaka Police Hospital
-
- Hatano Koji
- Department of Urology, Osaka Police Hospital
-
- Satoh Mototaka
- Department of Urology, Osaka Police Hospital
-
- Tsujimoto Yuichi
- Department of Urology, Osaka Police Hospital
-
- Honda Masahito
- Department of Urology, Osaka Police Hospital
-
- Matsumiya Kiyomi
- Department of Urology, Osaka Police Hospital
-
- Fujioka Hideki
- Department of Urology, Osaka Police Hospital
Bibliographic Information
- Other Title
-
- 大阪警察病院における前立腺癌症例の臨床的検討
- オオサカ ケイサツ ビョウイン ニ オケル ゼンリツセン ガン ショウレイ ノ リンショウテキ ケントウ
Search this article
Abstract
(Objectives) Treatment trends and outcomes for prostate cancer in our hospital were reported.<br>(Material and methods) A total of 482 patients with prostate cancer treated in our hospital between January, 1990 and December, 2004.<br>(Results) The age distribution was from 51 to 99 years-old, with the mean age of 72.9 years-old at onset. The number of prostate cancer patients, especially asymptomatic patients with PSA elevation, have increased recently. As for the clinical stage, 92 cases (19.1%), 238 cases (49.4%), 48 cases (10.0%) and 104 cases (21.6%) were stage A, B, C and D, respectively. 425 cases (88.2%) received some form of endocrine therapy. Retropubic prostatectomy or external beam radiation therapy was performed in 77 and 57 cases, respectively all cases. The cause-specific 5-year survival rate of the 482 cases was 79.7%, comprising 100% for stage A1, 96.8% for stage A2, 89.4% for stage B, 79.9% for stage C and 42.9% for stage D. The cause-specific 5-year survival was significantly better in the latter patients (1997-2004) than the former patients (1990-1996) in stage C (p=0.0226), D (p=0.0448). In stage C patients, the retropubic prostatectomy (with endocrine therapy) group, increased in the latter period and showed longer cause-specific 5-year survival than the endocrine therapy group (p=0.0027). In stage D2 patients, chemo-endocrine therapy with VP-16, ADM and CDDP refractory and cause-specific 5-year survival was longer than endocrine therapy alone (p=0.0467, P=0.0381).<br>(Conclusion) Our results suggest that retropubic prostatectomy with endocrine therapy and chemo-endocrine therapy are useful for stage C and D prostate cancer patients, respectively.
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 98 (5), 700-709, 2007
THE JAPANESE UROLOGICAL ASSOCIATION
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205055475328
-
- NII Article ID
- 110006345440
-
- NII Book ID
- AN00196577
-
- COI
- 1:STN:280:DC%2BD2svmsVGrsg%3D%3D
-
- ISSN
- 18847110
- 00215287
- http://id.crossref.org/issn/00215287
-
- NDL BIB ID
- 8896108
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed